DeAngelis, MD, MSK’s Chief Physician Executive, Scott M. “We are grateful to the Commonwealth Foundation for Cancer Research for their continued generosity that has enhanced our ability to pursue drug development and has led to numerous scientific innovations in cancer research, both at MSK and through the collaborative effort of Break Through Cancer,” said Lisa M. These cancers all share common features - low five-year survival rates, little to no effective early detection, and a lack of recent progress or innovation in treatment. Break Through Cancer unites five of the top cancer research centers in the world in a collaborative quest to find cures for several of the deadliest cancers. The center’s work complements MSK’s participation in Break Through Cancer, a first-of-its-kind multi-institutional initiative founded by the Commonwealth Foundation for Cancer Research in 2021.
The center has numerous drug candidates in preclinical testing and many in various stages of clinical trials, with a particular emphasis on finding treatments for some of the most resistant cancer types, including pancreatic, brain, and ovarian cancers. The Foundation’s pledge will support the Center for Experimental Therapeutics’ accelerated drug discovery program, which funds laboratory and preclinical investigations and clinical trials for new agents. “We are profoundly grateful to the Foundation for their continued support that will allow us to enhance drug development and discovery activities at MSK.” Scheinberg, MD, PhD, Chairman of the Center for Experimental Therapeutics Deputy Director for Therapeutic Discovery, Sloan Kettering Institute Break Through Cancer Board Member and Vincent Astor Chair. “The Commonwealth Foundation for Cancer Research has been our valued collaborator since day one, and their enduring commitment is at the heart of extraordinary advances that have significantly improved the lives of people with cancer,” said David A. It has also participated in the clinical research that has led to the first drug to target KRAS, a gene that is commonly mutated in lung, pancreatic, colon, and other difficult-to-treat cancers. The center has been integral in the advancement of revolutionary treatment approaches, including chimeric antigen receptor (CAR) T cell therapy, which is approved to treat blood cancers and is being tested for many other types of cancer, and checkpoint inhibitors, the immunotherapy drugs that have dramatically improved outcomes for some people with solid tumors such as melanoma. In this multidisciplinary research environment, scientists in the center have developed six novel treatments from the lab stage, which ultimately achieved regulatory approval, and 70 new technologies, which were later licensed to biotechnology or pharmaceutical companies. Since its founding, the Center for Experimental Therapeutics has become a powerhouse of cancer drug development with the goal of promoting research into promising new therapies and speeding the translation of discoveries from the laboratory to the bedside. With this gift, the Commonwealth Foundation for Cancer Research continues their nearly three-decade commitment to the Center for Experimental Therapeutics, which was initially founded in 2002 with a generous gift from the Foundation. Newswise - Memorial Sloan Kettering Cancer Center (MSK) today announced a transformative gift from the Commonwealth Foundation for Cancer Research to benefit the Center for Experimental Therapeutics, a multidisciplinary research and drug development group at MSK.
0 kommentar(er)
